Abstract
Although the use of oral analgesics for the control of cancer pain has been demonstrated to be successful in most patients, some patients will fail to respond to pharmacological therapy or will suffer unacceptable adverse effects. Experience is accumulating that when adverse effects prevail with oral opioid administration, the analgesic response may be improved by changing the drug and/or the route of administration. Switching to an alternative opioid may further improve the balance between analgesia and adverse effects Despite optimal systemic opioid treatment, in some complicated circumstances it is necessary to find different solutions, including the neuraxial administration of multiple drugs with different characteristics, which are difficult to manage. Three case reports illustrate how complex could be the analgesic approach using multiple analgesic regimens and different routes of administration to effectively manage complex pain syndromes commonly defined as unresponsive.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aldrete JA (1995) Reduction of nausea and vomiting from epidural opioids by adding droperidol to the infusate in home-bound patients. J Pain Symptom Manage 10:544–547
Borgbjerg FM, Svensson BA, Frigast C, Gordh T (1994) Histopathology after repeated intrathecal injections of preservative-free ketamine in the rabbit: a light and electron microscopic examination. Anesth Analg 79:105–111
Caraceni A, Zecca E, Martini C, De Conno F (1999) Gabapentin as an adjuvant to opioid analgesia for neuropathic cancer pain. J Pain Symptom Manage 17:441–445
Cherny NJ, Chang V, Frager G, et al (1995) Opioid pharmacotherapy in the management of cancer pain: a survey of strategies used by pain physicians for the selection of analgesic drugs and routes of administration. Cancer 76:1288–1293
Coyle N, Foley KM (1993) The use of multiple routes of opioid drug administration in an advanced cancer patient. J Pain Symptom Manage 8:234–237
Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden AM (1997) Epidural epinephrine and clonidine: segmental analgesia and effects on different pain modalities. Anesthesiology 87:785–794
Eisenach JC, DuPen S, Dubois M, et al (1995) Epidural clonidine analgesia for intractable cancer pain. Pain 61; 391–399
Mercadante S, Casuccio A, Agnello A, et al (1999) Rapid switching from methadone to morphine in cancer patients with poor response to morphine. J Clin Oncol 17:3307–3312
Mercadante S, Villari P, Fulfaro F (2001) Gabapentin for opioid-related myoclonus in cancer patients. J Support Care Cancer 9:205–206
Mercadante S (1996) Ketamine in cancer pain: an update. Palliat Med 10:225–230
Mercadante S (1999) Opioid rotation in cancer pain: rationale and clinical aspects. Cancer 86:1856–1866
Mercadante S (1999) Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 79:1–13
Mercadante S (1999) Treatment and outcome of cancer pain in advanced cancer patients followed at home. Cancer 85:1849–1858
Mercadante S (1998) Pathophysiology and treatment of myoclonus in cancer. Pain 74:5–9
Oneschuk D, Bruera E (2000) Respiratory depression during methadone rotation in a patient with advanced cancer. J Palliat Care 16:50–54
Stotz M, Oehen H-P, Gerber H (1999) Histological findings after long-term infusion of intrathecal ketamine for chronic pain: a case report. J Pain Symptom Manage 18:223–228
Yang CY, Wong CS, Chang JY, Ho ST (1996) Intrathecal ketamine reduces morphine requirements in patients with terminal cancer pain. Can J Anaesth 43:379–383
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mercadante, S., Villari, P. & Ferrera, P. Dialogues on complex analgesic strategies for difficult pain syndromes. Support Care Cancer 12, 599–603 (2004). https://doi.org/10.1007/s00520-003-0575-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-003-0575-0